EP0873113A1 - Skin treatment formulation and uses thereof - Google Patents

Skin treatment formulation and uses thereof

Info

Publication number
EP0873113A1
EP0873113A1 EP97900732A EP97900732A EP0873113A1 EP 0873113 A1 EP0873113 A1 EP 0873113A1 EP 97900732 A EP97900732 A EP 97900732A EP 97900732 A EP97900732 A EP 97900732A EP 0873113 A1 EP0873113 A1 EP 0873113A1
Authority
EP
European Patent Office
Prior art keywords
parts
hydrolysed
preparation according
equivalent
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97900732A
Other languages
German (de)
English (en)
French (fr)
Inventor
Guido Paduano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0873113A1 publication Critical patent/EP0873113A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8164—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a compound for the treatment of skin pathologies and unaesthetic conditions and optionally of pathologies of the skin and related tissues. More particularly, the invention relates to a product for the treatment of: 1. skin atrophy striae, 2 skin wrinkles,
  • the invention also relates to the uses of the said compound.
  • Background art Skin atrophy and the phenomena associated therewith are mainly due to a deficiency in the two proteins of the skin, collagen and elastin, the first being responsible for nourishing and revitalizing the skin tissues while the second has the function of making the skin tissues elastic.
  • the subject of the present invention is a product for the treatment of skin pathologies and unaesthetic conditions and optionally of pathologies of the skin, based on elastin and collagen, which product makes it possible to obtain better and especially longer lasting results.
  • the product of the invention contains a combination of at least the following components: 1) collagen, 2) elastin,
  • a suitable vehicle which may also consist of a physiologically acceptable solution, depending on the type of administration for which the formulation is intended.
  • vascularization In certain cases, a reduction in vascularization accompanies the unaesthetic skin conditions mentioned.
  • administration of the optional local vasodilator together with the collagen and elastin makes it possible to re-establish peripheral blood circulation in the zone treated, thereby giving rise to localized vasodilation and thus allowing the two proteins to reach the treated zones.
  • the temporary vasodilation produced by the vasodilatory substance helps vascularization in the tissues and facilitates the provision of nutrients by the blood.
  • RNA helps the tissues receiving it to manufacture proteins with characteristics similar to the proteins administered, while RNA serves to create a memory, in the tissues receiving it, for the two proteins supplied in order to allow the tissues themselves to reproduce these proteins.
  • RNA or DNA therefore makes it possible to accelerate the healing process by stimulating the autonomous production of collagen and elastin by the skin tissues being treated.
  • the two acids are preferably used in combination, but appreciable results may also be obtained with only one of the two acids or the respective salt.
  • the compound may comprise, besides the four main components referred to above, one or more secondary components chosen from one or more of the following groups: amino acids; - enzymes and coenzymes; Vitamin C keratin (restricted to treatment of the scalp) .
  • useful enzymes for the use according to the invention are the following: pepsin, pyridoxine (Vitamin B6 coenzyme) , biotin or Vitamin H (Vitamin B6 coenzyme) .
  • pepsin pyridoxine
  • pyridoxine Vitamin B6 coenzyme
  • biotin or Vitamin H Vitamin H
  • the amino acids added to the formulation metabolize the proteins, that is to say they are involved in the formation of collagen and elastin.
  • the enzymes and coenzymes are catalysts of the process of protein metabolism, that is to say they increase the rate of biochemical reaction of the amino acids to proteins. Their presence in combination with amino acids therefore accelerates the metabolization of protein.
  • antioxidant represented by Vitamin C
  • Keratin the use of which is limited to formulations for treating the scalp, constitutes specific nourishment for promoting the regrowth and strengthening of the hair.
  • composition of the product varies depending on the mode of administration, in particular as regards the vehicles and the excipients.
  • the four fundamental components or five in the case of the use of both DNA and RNA
  • they may be used in the following amounts, expressed in parts by weight, including in the absence of other components: Hydrolysed collagen: 3-10 parts
  • RNA Sodium ribonucleate (RNA) 3-10 parts Excipients and vehicles qs
  • the sodium deoxyribonucleate and ribonucleate can be used independently of or in combination with each other.
  • compositions varying within the following ranges, again expressed in parts by weight:
  • RNA Sodium ribonucleate 4-8 parts in the presence of appropriate vehicles and/or excipients.
  • appropriate vehicles and/or excipients for administration by subcutaneous or intradermal injection or infiltration, the components mentioned above are prepared in a physiological solution, which in this case represents the vehicle. Typically, the parts by weight shown above are combined with 1000 parts by weight of physiological solution.
  • Appropriate excipients and vehicles are used for topical administration, and a few examples of these will be given in the following text together with respective amounts, with respect to a few particularly effective formulations.
  • secondary components such as certain enzymes and amino acids.
  • a formulation to which all the secondary components mentioned above have been added is given below.
  • the composition relates to an amount of 10 ml, equivalent to 10 g in physiological solution:
  • Vitamin C 350-650 mg Hydrolysed keratin (*) 20-40 mg
  • compositions given above remain valid for topical application as regards the first fifteen components, except that they would be in a different and— higher concentration, in view of the increased difficulty of absorption and the increased dispersion. Moreover, the physiological solution would be replaced by a combination of various vehicles and excipients.
  • compositions may be used, relative to 10 g of product (where the preferred amounts, again in mg, are shown in parentheses) :
  • Hydrolysed collagen 65-200 mg 90-170
  • Procaine hydrochloride 20-60 mg (30-50)
  • Vehicle hydrogenated polyoxyethylenated castor oil 100-300 mg (150-230)
  • ampules for topical use in the treatment of atrophy in which case the excipient is replaced by water, with the addition of preserving agents.
  • Ampules for the treatment of the scalp may have the same composition as ampules for the treatment of atrophy, with the addition of keratin in an amount of from 60 to 120 mg per 10 g of product.
  • the DNA and the RNA may also be used in the form of potassium deoxyribonucleate and potassium ribonucleate or in another compatible form.
  • the application methods vary depending on the type of treatment and on the route of administration. The latter may be carried out topically or by infiltration via subcutaneous, intra- or mesodermal injection of the compound into the site of the atrophies.
  • the number of applications and the amount of product applied vary according to the area of tissue to be treated and its condition. A few general indications are given below, which a person skilled in the art will use as a guideline for selecting the most suitable mode of application in each individual case.
  • Treatment of cutaneous striae subcutaneous infiltrations are performed, using a syringe with a microneedle, by inserting the needle parallel to the surface of the stria along its entire length.
  • a tunnel is formed which is filled with the solution as the needle is withdrawn.
  • intradermal infiltrations are performed, using a syringe with a microneedle, by inserting the needle parallel to the surface of the wrinkle along its entire length.
  • a tunnel is formed- which is filled with the solution as the needle is withdrawn.
  • mesodermal infiltrations that is to say infiltrations into the dermis but to a deeper level than intradermal infiltrations
  • a syringe with a microneedle in order to provide deep and diffuse nourishment for the tissues concerned.
  • Treatment of the scalp and of alopecia intradermal infiltrations into the scalp (trichomesotherapy) are performed using a syringe with a microneedle.
  • Treatment of skin chapping intradermal infiltrations are performed into the area concerned using a syringe with a microneedle. 6. Treatment of slow cicatrization: intradermal infiltrations are performed into the area concerned using a syringe with a microneedle.
  • the number of applications depends on the seriousness of the condition of the tissue treated. In general, the number of applications may range from 5 to 50.
  • the amount of solution administered varies according to the size of the area under treatment. Generally speaking, about 0.1 ml of product per cm 2 of tissue treated may be applied in the treatment of cutaneous striae.
  • Cosmetic treatment by means of topical application of the compound is carried out by rubbing the ampule preparation onto the area to be treated or by massaging into the area concerned in the case of cream preparations.
  • Topical use involves application twice daily over a period varying between one and six months, depending on the seriousness of the condition of the skin tissue.
  • NaCI queous solution (0.9%): stabilized pig-collagen 30 g/l sterilized pig-elastin 10/15 g/l glycine 2/4 g/l proline 6/10 g/l hydroxyproline 2/4 g/l
  • Collagen and elastin may be of animal or vegetal origin.
  • a process for obtaining hydrolysed cross ⁇ linked collagen and hydrolysed cross-linked elastin is described hereinbelow:
  • A.stabilised pig-collagen is mixed in a vacutainer under nitrogen atmosphere at 35/38° for 90 min.; B.the product is filtered on a 1-micrometre filter;
  • steps C, D and E are repeated;
  • gelatine On the bottom of the container a translucent homogeneous gelatine is collected.
  • the gelatine may be brought at the desired viscosity by addition of a sterilized 0.9% acqueous solution of NaCI.
  • Hydrolized aminoacids, hydrolized DNA and RNA and hydrolized biotin as well as procaine hydrocloride are added to the proteins treated as above described in order to obtain the above preparation.
  • the same process can be used with twice the amount of elastin and collagen (i.e. 60 g/l collagen and 20/30 g/l elastin.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP97900732A 1996-01-10 1997-01-08 Skin treatment formulation and uses thereof Withdrawn EP0873113A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI960002 1996-01-10
IT96FI000002A IT1289845B1 (it) 1996-01-10 1996-01-10 Formula per il trattamento della cute e suoi impieghi
PCT/IT1997/000002 WO1997025023A1 (en) 1996-01-10 1997-01-08 Skin treatment formulation and uses thereof

Publications (1)

Publication Number Publication Date
EP0873113A1 true EP0873113A1 (en) 1998-10-28

Family

ID=11351445

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97900732A Withdrawn EP0873113A1 (en) 1996-01-10 1997-01-08 Skin treatment formulation and uses thereof

Country Status (6)

Country Link
EP (1) EP0873113A1 (enrdf_load_stackoverflow)
AU (1) AU709842B2 (enrdf_load_stackoverflow)
BR (1) BR9706943A (enrdf_load_stackoverflow)
CA (1) CA2242636A1 (enrdf_load_stackoverflow)
IT (1) IT1289845B1 (enrdf_load_stackoverflow)
WO (1) WO1997025023A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758458B1 (fr) * 1997-01-21 2000-01-07 Jean Noel Thorel Produits cosmetiques ou dermo-pharmaceutiques respectant l'ecologie cutanee
BR0214259A (pt) * 2001-11-27 2004-09-21 Unilever Nv Composição aquosa de tratamento capilar, uso da mesma e método para tratamento dos cabelos
US7235249B2 (en) * 2002-03-28 2007-06-26 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions
IT1393422B1 (it) * 2009-03-23 2012-04-20 Nicoletti Composizione cosmetica contenente collagene ed elastina
WO2012101473A1 (en) * 2011-01-27 2012-08-02 Abdula Kurkayev Nanocomposite formulations and method of skin care treatment for rejuvanation and correction of skin defects
JP5997485B2 (ja) * 2012-04-16 2016-09-28 山口　勝美 肌質改善組成物及びその製造方法
ES2969933T3 (es) 2012-12-31 2024-05-23 Jrx Biotechnology Inc Formulaciones farmacéuticas tópicas líquidas en nanoemulsión
WO2017048807A1 (en) 2015-09-17 2017-03-23 Jrx Biotechnology, Inc. Approaches for improving skin hydration or moisturization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1256235A (en) * 1966-06-20 1971-12-08 Rumanian Minister Of The Food Cream for the care and regeneration of the skin
FR2592790A1 (fr) * 1986-01-16 1987-07-17 Villano Guy Preparation cosmetique a action regeneratrice et antirides
IT1215392B (it) * 1987-03-23 1990-02-08 Denis R P Spa Formulazioni cosmetiche
FR2609393A1 (fr) * 1988-02-23 1988-07-15 Serobiologiques Lab Sa Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques comprenant une substance azotee, notamment aminoacides, oligo- ou polypeptides, proteines, et leurs derives, et composition pharmaceutique ou cosmetique ainsi preparee.
ATE154230T1 (de) * 1990-08-14 1997-06-15 Kenneth M Hallam Haarwuchsmittel
JP3202810B2 (ja) * 1992-10-15 2001-08-27 協和醗酵工業株式会社 化粧料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9725023A1 *

Also Published As

Publication number Publication date
ITFI960002A0 (enrdf_load_stackoverflow) 1996-01-10
ITFI960002A1 (it) 1997-07-10
CA2242636A1 (en) 1997-07-17
AU1318597A (en) 1997-08-01
BR9706943A (pt) 1999-04-06
AU709842B2 (en) 1999-09-09
WO1997025023A1 (en) 1997-07-17
IT1289845B1 (it) 1998-10-16

Similar Documents

Publication Publication Date Title
AU611915B2 (en) Method for inducing biological coverings in wounds
US6270811B1 (en) Pharmaceutical, cosmetic composition with base of microbial culture mixed with an essential oil and an acid
US8603973B2 (en) Skincare composition comprising HSA fusion protein, preparation method and uses thereof
KR20120089433A (ko) 충전제와 섬유아세포 성장 배지를 조합한 주사용 조성물
WO1992007877A1 (en) Hair growth regulating composition comprising epithelium cell supernatant-derived growth factor
CA2042014A1 (en) Method of treating or preventing baldness with compositions containing fibroblast growth factor
CN101453985A (zh) 促进毛发生长的组合物
JPS63185918A (ja) 化粧用組成物
ZA200606515B (en) Use of low-dose erythropoietin for the treatment of acute or chronic kidney failure and for the treatment of wounds
CN1160582A (zh) 含有细胞生长因子的皮肤外用组合物
JP3321712B2 (ja) マツエキス含有外用養毛剤
AU709842B2 (en) Skin treatment formulation and uses thereof
US6858201B2 (en) Methods for treating fingernails and toenails
RU2202362C2 (ru) Композиция для местного применения, содержащая фактор роста эпидермиса человека
US20200164037A1 (en) Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
GB2210789A (en) Topical application for skin care
CN101596310A (zh) 一种用于创面修复的人工基底膜乳膏
JPS617209A (ja) 育毛剤組成物
RU2292906C2 (ru) Фармацевтические и косметические композиции, содержащие плацентарный фактор роста plgf-1
US20050276766A1 (en) Methods and compositions for increasing skin remodeling
US20040234476A1 (en) Cosmetic preparation with anti-wrinkle action
CA2525670A1 (en) Hair regenerator
JPH01305010A (ja) 化粧料
HK1078469B (en) Pharmaceutical and cosmetic compositions comprising plgf-1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980730

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010801